Press Releases

Press Releases

July 6, 2015
BOSTON , July 6, 2015 /PRNewswire/ -- Akcea Therapeutics, a wholly-owned subsidiary of Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), announced today that the U.S. Food and Drug Administration has granted Orphan Drug Designation to volanesorsen (ISIS-APOCIII Rx ) for the treatment of patients with
May 28, 2015
CARLSBAD, Calif. , May 28, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast: What:    Akcea Therapeutics Webcast When:    Thursday, June 4 at 1:00 p.m. ET / 10:00 a.m.